Subcutaneous injections of apoA‐I/HDL‐C mimetic peptides inhibited tumor development in multiple mouse models including ovarian and colon cancer.16, 17 Moreover, these anti‐tumor effects of apoA‐I/HDL‐C require an immunocompetent host. This evidence concerns the gene APOA1 and neoplasm.